Clinical Research Directory
Browse clinical research sites, groups, and studies.
Back to Studies
RECRUITING
NCT06433765
A Study Evaluating the Effect of BRIUMVI® (Ublituximab) on Pregnancy and Infant Outcomes in Participants With Multiple Sclerosis (MS)
Sponsor: TG Therapeutics, Inc.
View on ClinicalTrials.gov
Summary
The primary objective of the study is to compare the prevalence rate of major congenital malformations (MCM) between 2 cohorts of pregnant participants with MS who are exposed to BRIUMVI® and who are unexposed to BRIUMVI®.
Official title: BRIUMVI® Pregnancy Registry: A Prospective Study of Pregnancy and Infant Outcomes in Patients Treated With BRIUMVI®
Key Details
Gender
FEMALE
Age Range
15 Years - 50 Years
Study Type
OBSERVATIONAL
Enrollment
728
Start Date
2024-06-01
Completion Date
2035-03-31
Last Updated
2026-04-03
Healthy Volunteers
No
Conditions
Interventions
OTHER
No intervention
No intervention
Locations (1)
BRIUMVI® Pregnancy Registry Virtual Research Coordination Center
Wilmington, North Carolina, United States